[A21-51] Olaparib (prostate cancer) - Addendum to Commission A20-106
Last updated 04.06.2021
Project no.:
A21-51
Commission:
Commission awarded on 27.04.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent
Patients for whom abiraterone or enzalutamide is the best individual choice: hint of considerable added benefit.
Patients for whom docetaxel or cabazitaxel is the best individual choice: added benefit not proven.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A20-106 | Olaparib (prostate cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021.06.04 A G-BA decision was published.